Aspire Biopharma Holdings (ASBP) EPS (Basic) (2021 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly EPS (Basic) of -$20.57 for Q1 2026, up 95.93% year-over-year from -$10.5 in Q1 2025, and up 87.32% quarter-over-quarter from -$162.2 in Q4 2025.
Aspire Biopharma Holdings (ASBP) EPS (Basic) (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported EPS (Basic) for 6 consecutive years, with -$20.57 the latest figure, recorded in Q1 2026.
- In Q1 2026, EPS (Basic) rose 95.93% year-over-year to -$20.57; the TTM figure through Mar 2026 stood at -$88.91 (up 83.82% YoY), while the FY2025 annual figure was -$388.1, down 1208.78% from the prior year.
- EPS (Basic) improved to -$20.57 in Q1 2026 per ASBP's latest filing, from -$162.2 in the prior quarter.
- Across five years, EPS (Basic) topped out at $110.76 in Q2 2023 and bottomed at -$504.87 in Q1 2025.
- Historically, EPS (Basic) has averaged -$65.93 across 5 years, with a median of -$8.59 in 2023.
- Annual changes were most pronounced in 2023 — EPS (Basic) soared 10893.01% — and 2025, when it slumped 11413.34%.
- Aspire Biopharma Holdings' EPS (Basic) stood at -$4.34 in 2022, then slumped by 83.08% to -$7.95 in 2023, then jumped by 82.27% to -$1.41 in 2024, then plunged by 11413.34% to -$162.2 in 2025, then soared by 87.32% to -$20.57 in 2026.
- Business Quant data shows ASBP's EPS (Basic) at -$20.57 in Q1 2026, -$162.2 in Q4 2025, and -$63.62 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 1.23 |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -0.72 |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -0.06 |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 0.18 |
| 10 | Aspire Biopharma Holdings | 8.34 Mn | -3.83 Mn | -30,086.00 | -1.22 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.22 |
| Mar 31, 2026 | -20.57 |
| Dec 31, 2025 | -162.20 |
| Sep 30, 2025 | -63.62 |
| Mar 31, 2025 | -504.87 |
| Dec 31, 2024 | -1.41 |
| Sep 30, 2024 | -33.42 |
| Jun 30, 2024 | -85.37 |
| Mar 31, 2024 | -329.25 |
| Dec 31, 2023 | -7.95 |
| Sep 30, 2023 | -9.24 |
| Jun 30, 2023 | 110.76 |
| Mar 31, 2023 | 23.98 |
| Dec 31, 2022 | -4.34 |
| Sep 30, 2022 | 35.97 |
| Jun 30, 2022 | 1.01 |
| Mar 31, 2022 | -4.38 |
| Dec 31, 2021 | -0.14 |
| Sep 30, 2021 | -2.94 |
| Mar 31, 2021 | -2.70 |